Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#4067
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$71.45
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-4.13%
Change (1 year)
100.42%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Earnings for Dianthus Therapeutics, Inc. (DNTH)
Earnings in Jun 2026 TTM: $-29.91M
According to Dianthus Therapeutics, Inc. latest financial reports the company's current earnings are $-29.91M. In 2023 the company made an earning of $-43.56M, a decrease compared to its 2022 earnings that were of $-28.48M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Dianthus Therapeutics, Inc. from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-29.91M | -64.80% |
| 2024 | $-84.97M | 95.08% |
| 2023 | $-43.56M | 52.95% |
| 2022 | $-28.48M | 117.22% |
| 2021 | $-13.11M | -82.51% |
| 2020 | $-74.94M | -2.39% |
| 2019 | $-76.77M | 33.48% |
| 2018 | $-57.52M | 62.06% |
| 2017 | $-35.49M | 276.32% |
| 2016 | $-9.43M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -17,736.50% |
US
|
|
| $-3.09B | 10,221.31% |
US
|
|
| $-4.02B | 13,328.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -6,621.95% |
NL
|
